Buy article

Volume: 0 - Issue: 0

First page: 0 - Last page: 0

G. Petit - A. Coudert - R. Hermann - E. Truy - M. Bonjour - P. Reix - S. Ayari

DOI: 10.4193/Rhin24.533

BACKGROUND: New CFTR Modulator triple therapy Elexacaftor-Tezacaftor-Ivacaftor (ETI) has proven efficacy in pulmonary outcomes. However, its qualitative impact via sinonasal imaging in children has not been specifically studied. The aim of our study is to assess the impact of ETI triple therapy through sinus imaging in children with Cystic Fibrosis (CF) aged 6–12 years.
METHODS: This prospective, single-center study, covered children with CF aged 6-12 years, all undergoing annual low-dose CT scans of the sinuses and lungs. The main objective of our study is the evaluation of the evolution of the modified Lund-Mac Kay (mLMK) score. Evaluations occurred at baseline and after one year of ETI therapy. Secondary objectives included the identification of potential associations between mLMK score and Sinus and Nasal Quality of Life Survey Score (SN-5) score, as well as examination of mLMK score changes in individual sinuses.
RESULTS: 26 patients were enrolled in our study. The median mLMK score significantly improved after one year of ETI therapy. Significant correlation was observed between mLMK and SN-5 scores.
CONCLUSION: This study highlights ETI’s efficacy in improving sinonasal involvement in children aged 6 to 12 with CF. This is in line with the observations of clinical improvement, and presents an alternative to sinus surgery, thus potentially leading to a reduction in surgical interventions.

Rhinology 0-0: 0-0, 0000